The chronic pharmacotherapy of gout is based on three major strategies: inhibition of uric acid production (e.g. xanthine oxidase (XO) inhibitors), enhancement of the renal excretion of uric acid (e.g. uricosurics) and the degradation of uric acid produced (e.g. application of recombinant uricases).20 This evidence concerns the gene XDH and gout.